The use of β-blockers after myocardial infarction: no doubts remain.

This review article examines the contemporary evidence supporting the use of beta-blockers following myocardial infarction (MI), particularly in the era of early revascularization and modern medical therapies. It concludes that beta-blockers remain a cornerstone therapy for MI patients, especially those with left ventricular dysfunction, by reducing recurrent events and improving survival. The authors emphasize that despite evolving MI management, the benefits of beta-blockers are well-established and continue to warrant their routine prescription. This reinforces the clinical importance of beta-blocker therapy in post-MI care, highlighting their sustained role in improving patient outcomes.